[Non-alcoholic fatty liver disease (NAFLD)]

Area of Science:

• Hepatology
• Metabolic Diseases
• Public Health

Background:

• Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition in Europe and the USA.
• NAFLD prevalence is increasing globally.
• Metabolic syndrome components (diabetes, obesity, dyslipidemia) are key risk factors for NAFLD.

Purpose of the Study:

• To highlight the significance of identifying patients with non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis.
• To emphasize the increased mortality risk associated with NASH and significant fibrosis.
• To underscore the current lack of specific NASH treatments and the priority of managing risk factors.

Main Methods:

• Review of epidemiological data on NAFLD prevalence.
• Analysis of risk factors associated with NAFLD progression.
• Assessment of clinical outcomes and mortality in NASH patients.

Main Results:

• NAFLD affects a large and growing patient population, particularly those with metabolic syndrome.
• A subset of NAFLD patients (5-20%) progress to NASH, with potential for liver fibrosis and cirrhosis.
• NASH patients and NAFLD patients with advanced fibrosis face elevated mortality risks.

Conclusions:

• Early identification of NASH and significant liver fibrosis is critical for risk stratification.
• Management of metabolic syndrome and associated risk factors is a primary therapeutic strategy in the absence of specific NASH treatments.
• Further research into targeted NASH therapies is warranted.